Neutralizing antibodies are antibodies with antiviral activity that can recognize the viral surface protein, thereby blocking the specific receptor on the cell surface to which the virus binds. Genevoyager has developed a pseudovirus vector packaged with the SARS-CoV-2-S protein and a cell line overexpressing the ACE2 receptor. These products can be combined to establish cellular/animal-level SARS-CoV-2-S infection models, allowing for the study of the infection mechanism, drug development, analysis of the efficacy of neutralizing antibodies, and evaluation of vaccine development for SARS-CoV-2-S.